Guardant Health Launches Guardant Reveal® Ultra to Deliver Leading Sensitivity in MRD Testing
Business Wire•19/11/2026•16:43 ET
2
Key Highlights
- ➤Guardant Health launches U.S. clinical Guardant Reveal Ultra for solid-tumor MRD testing
- ➤Reveal Ultra demonstrates detection sensitivity at 1 ppm or below across major tumor types
- ➤Reveal Ultra validated using tissue samples containing as little as 5% tumor cellularity
- ➤Guardant Health completes precision oncology portfolio spanning MRD, genomic profiling, and therapy monitoring
Expert Statements
Helmy Eltoukhy, Chairman and co-CEO of Guardant Health
“Reveal Ultra opens a new frontier in MRD detection”
Helmy Eltoukhy, Chairman and co-CEO of Guardant Health
“While detecting cancer at one part per million has become an important benchmark, what truly matters is delivering that level of sensitivity reliably across real clinical samples and a broad range of tumor types. Reveal Ultra was built to meet that challenge, bringing extraordinary precision to everyday clinical practice and advancing our ability to track and manage each patient’s cancer throughout their journey.”
Guardant Health Launches Guardant Reveal(®) Ultra to Deliver Leading Sensitivity in MRD Testing
* Next-generation MRD test with detection sensitivity across major tumor types at 1 part per million or below
Get started
Create a free account to read the full story.
